Acute myeloid leukemia (AML) is a uncommon and aggressive most cancers of the blood and bone marrow. On April 21, World AML Day, the main target is on innovation and our dedication to the struggle towards hematologic cancers.
Understanding acute myeloid leukemia
Acute myeloid leukemia (AML) is a uncommon illness that primarily impacts the aged. It’s a most cancers of the blood and bone marrow that progresses quickly within the absence of therapeutic administration.
10%
The five-year survival fee for +60-year-old sufferers with AML is lower than 10%1
This most cancers is a proliferation of immature cells, i.e., cells that aren’t sufficiently developed and due to this fact can’t operate usually. These most cancers cells are current within the blood, which is why we communicate of “leukemia”; they arrive from a myeloid blast, therefore the time period “myeloid.”
Analysis & innovation, our leitmotif at Servier
Our ambition is obvious: to speed up the analysis and discovery of recent therapeutic options, guided by a long-term imaginative and prescient.
Our groups mobilize every single day to find and develop medicines the place sufferers’ wants are best.
Confronted with the continuous enhance in most cancers circumstances and the rising want for therapeutic options, we have now made oncology certainly one of our strategic priorities and dedicate over 70% of our R&D price range to it. Our ambition is to change into a targeted and progressive participant in most cancers remedies, notably hard-to-treat cancers the place the wants are, for essentially the most half, not but lined, similar to AML.
Collaborating with sufferers
With a purpose to greatest meet affected person wants, we work with them at each stage of the drugs lifecycle.
We collaborate with the worldwide community of affected person organizations ALAN (Acute Leukemia Advocates Community) to establish and higher incorporate the wants of individuals residing with leukemia.
[1] Betul Oran, Daniel J. Weisdorf. Survival for older sufferers with acute myeloid leukemia: a population-based research. Haematologica 2012;97(12):1916-1924; https://doi.org/10.3324/haematol.2012.066100.
